Dr David Robert Grimes looks at the eye health issues that are making the news.
NHS to save millions on AMD treatment
A landmark ruling promises to substantially reduce the cost of treating wet age-related macular degeneration (AMD) – and has significant implications for future drug policy. Bayer and Novartis had attempted to stop clinical commissioning groups (CCGs) from prescribing Avastin – a widely used and cheaper treatment, but unlicensed for AMD.
In September, the High Court ruled against the drug giants.
Sign in to continue
Not already a member of the College?
Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.
The number of people with glaucoma, AMD and cataracts is set to increase over the next 10 years. This new online tool will be a critical planning resource for commissioners and providers of eye health care.
The virtual Hospital Eye Service experience replaces the in-person experience pre-registration trainees would normally have gained in a hospital setting.
